Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar;153(3):1039-48.
doi: 10.1210/en.2011-1499. Epub 2011 Dec 13.

Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes

Affiliations
Review

Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes

Philip E Cryer. Endocrinology. 2012 Mar.

Abstract

Pancreatic islet α-cell glucagon secretion is critically dependent on pancreatic islet β-cell insulin secretion. Normally, a decrease in the plasma glucose concentration causes a decrease in β-cell insulin secretion that signals an increase in α-cell glucagon secretion during hypoglycemia. In contrast, an increase in the plasma glucose concentration, among other stimuli, causes an increase in β-cell insulin secretion that signals a decrease, or at least no change, in α-cell glucagon secretion after a meal. In absolute endogenous insulin deficiency (i.e. in type 1 diabetes and in advanced type 2 diabetes), however, β-cell failure results in no decrease in β-cell insulin secretion and thus no increase in α-cell glucagon secretion during hypoglycemia and no increase in β-cell insulin secretion and thus an increase in α-cell glucagon secretion after a meal. In type 1 diabetes and advanced type 2 diabetes, the absence of an increment in glucagon secretion, in the setting of an absent decrement in insulin secretion and an attenuated increment in sympathoadrenal activity, in response to falling plasma glucose concentrations plays a key role in the pathogenesis of iatrogenic hypoglycemia. In addition, there is increasing evidence that, in the aggregate, suggests that relative hyperglucagonemia, in the setting of deficient insulin secretion, plays a role in the pathogenesis of hyperglycemia in diabetes. If so, abnormal glucagon secretion is involved in the pathogenesis of both hypoglycemia and hyperglycemia in diabetes.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Physiology (in nondiabetes) and pathophysiology (in absolute endogenous insulin-deficient type 1 diabetes and advanced type 2 diabetes) of the intimate relationship between the inhibitory effect of pancreatic β-cell insulin secretion on pancreatic islet α-cell glucagon secretion in humans. Normally a decrease in plasma glucose causes a decrease in β-cell insulin secretion that signals an increase in α-cell glucagon secretion during hypoglycemia. An increase in plasma glucose, among other nutrients, causes an increase in β-cell insulin secretion that prevents an increase in α-cell glucagon secretion in response to those nutrients after a mixed meal. On the other hand, in the setting of β-cell failure in type 1 diabetes and advanced type 2 diabetes, a decrease in plasma glucose cannot cause a decrease in β-cell insulin secretion, and the absence of that signal results in no increase in pancreatic α-cell glucagon secretion during hypoglycemia. Conversely, in the setting of β-cell failure, an increase in plasma glucose, among other nutrients, cannot cause an increase in β-cell insulin secretion, and the absence of that restraining signal results in an increase in pancreatic α-cell glucagon secretion after a mixed meal.

Similar articles

Cited by

References

    1. Cherrington AD. 2001. Control of glucose production in vivo by insulin and glucagon. In: Jefferson LS, Cherrington AD, eds. Handbook of physiology. Section 7: the endocrine system. Vol II: the endocrine pancreas and regulation of metabolism. New York: Oxford University Press; 759–785
    1. Gustavson SM, Chu CA, Nishizawa M, Farmer B, Neal D, Yang Y, Vaughan S, Donahue EP, Flakoll P, Cherrington AD. 2003. Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion. Am J Physiol Endocrinol Metab 285:E534–E544 - PubMed
    1. Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD. 2011. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 13(Suppl 1):118–125 - PMC - PubMed
    1. McGarry JD, Foster DW. 1980. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 49:395–420 - PubMed
    1. Xiao C, Pavlic M, Szeto L, Patterson BW, Lewis GF. 2011. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes 60:383–390 - PMC - PubMed

Publication types